Skip to main content
SpringerLink
Log in

Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Female BDF1 mice inoculated with MXT (3.2) estrogen independent mouse mammary carcinoma were treated for three weeks with microcapsules of the luteinizing hormone-releasing hormone (LH-RH) agonist [D-Trp6]LH-RH, the antagonist SB-75, the somatostatin analog RC-160, or combinations. The lack of estrogen dependence of the tumor was proved by bilateral surgical ovariectomy, which had no effect. In two experiments, treatment with 25µg/day doses of each analog alone resulted in a significant inhibition of tumor growth as shown by a 40–53% inhibition of tumor volumes, 38–43% decrease in tumor weights, and histological signs of tumor regression. However, the combination of SB-75 or [D-Trp6]LH-RH with somatostatin analog RC-160 caused greater reduction of tumor volume (68 and 61%) or tumor weights (59 and 56%), than single analogs, and histologically the occurrence of apoptosis and decrease in AgNOR numbers was more pronounced in the groups receiving combination therapy. Specific binding sites for [D-Trp6]LH-RH, EGF, and IGF-I were demonstrated in the tumor membranes. The binding capacity of LH-RH receptors was decreased by treatment with the analogs, the greatest down-regulation being caused by combination therapy. A significant decrease in EGF binding capacity was observed after treatment with the LH-RH analogs, alone or especially in combination with somatostatin analog RC-160. The combination of these analogs also caused a reduction in IGF-I receptors. The finding that LH-RH agonists and antagonists and somatostatin analogs inhibit the growth of estrogen independent mammary tumors, and that combinations are more effective than single analogs, might be of practical importance in human breast cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Davidson NE, Lippman ME: Treatment of metastatic breast cancer. In: Lippman ME, Lichter AS, Danforth DN (eds) Diagnosis and Management of Breast Cancer. WB Saunders Co., Philadelphia, 1988, pp 375–406

    Google Scholar 

  2. Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles T, Lister TA: The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol 15: 171–173, 1985

    Article  PubMed  Google Scholar 

  3. Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocrine Rev 11: 221–265, 1990

    Google Scholar 

  4. Schally AV, Comaru-Schally AM, Redding TW: Antitumor effects of analogs of hypothalamic hormones in endocrine dependent cancers. Proc Soc Exp Biol Med 175: 259–281, 1984

    PubMed  Google Scholar 

  5. Redding TW, Schally AV: Inhibition of mammary tumor growth in rats and mice by administration of agonistic analogs of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 80: 1459–1462, 1983

    PubMed  Google Scholar 

  6. Klijn JGM: Long-term LHRH agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med Oncol Tumor Pharmacother 1: 123–128, 1984

    PubMed  Google Scholar 

  7. Nicholson RI, Walker KJ, Walker RF, Read GF, Turkes A, Robertson JFR, Blamey RW: Review of the endocrine actions of LHRH analogs in premenopausal women in breast cancer. Hormone Res 32: 198–201, 1989

    Google Scholar 

  8. Harvey HA, Lipton A, Max D: LH-RH analogs for human mammary carcinoma. In: Vickery BH, Nestor JJ Jr, Hafez ESE (eds) LH-RH and its Analogs-Contraceptive and Therapeutics Applications. MTP Press, Boston/Lancaster, 1984, p 329

    Google Scholar 

  9. Plowman PN, Nicholson RI, Walker KJ: Remission of postmenopausal breast cancer during treatment with the luteinizing hormone releasing hormone agonist ICI 118630. Br J Cancer 54: 903–909, 1986

    PubMed  Google Scholar 

  10. Schwartz L, Guiochet N, Keiling R: Two partial remissions induced by an LHRH analog in two postmenopausal women with metastatic breast cancer. Cancer 62: 2498–2500, 1988

    PubMed  Google Scholar 

  11. Sharoni Y, Bosin E, Miinster A, Levy J, Schall AV: Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86: 1648–1651, 1989

    PubMed  Google Scholar 

  12. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 131: 231–233, 1985

    Article  Google Scholar 

  13. Fekete M, Wittliff JL, Schally AV: Characteristics and distribution of receptors for [D-Trp6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3: 137–147, 1989

    PubMed  Google Scholar 

  14. Eidne KA, Flanagan CA, Harris NS, Millar RP: Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64: 425–432, 1987

    PubMed  Google Scholar 

  15. Darbre PD, Glover JF, King RJB: Effects of steroids and their antagonists on breast cancer cells: Therapeutic implications. Rec Results Cancer Res 113: 16–28, 1989

    Google Scholar 

  16. Manni A, Boucher AE, Demers LH, Harvey HA, Lipton A, Simmonds MA, Bartholomew M: Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 14: 289–298, 1989

    Article  PubMed  Google Scholar 

  17. Schally AV: Oncological applications of somatostatin analogs. Cancer Res 48: 6977–6985, 1988

    PubMed  Google Scholar 

  18. Szende B, Lapis K, Redding TW, Srkalovic G, Schally AV: Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin. Breast Cancer Res Treat 14: 307–314, 1989

    Article  PubMed  Google Scholar 

  19. Szende B, Srkalovic G, Groot K, Lapis K, Schally AV: Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. J Natl Cancer Inst 82: 513–517, 1990

    PubMed  Google Scholar 

  20. Bajusz S, Csernus V, Janaky T, Bokser L, Fekete M, Schally AV: New anatagonists of LH-RH. II. Inhibition and potentiation of LH-RH by closely related analogues. Int J Peptide Protein Res 32: 425–435, 1988

    Google Scholar 

  21. Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV: Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci USA 83: 1896–1900, 1986

    PubMed  Google Scholar 

  22. Schally AV: The use of LH-RH analogs in gynecology and tumor therapy. In: Belfort P, Pinotti JA, Eskes TKAB (eds) Advances in Gynecology and Obstetrics: General Gynecology, Vol 6. Parthenon Publishers, Carnforth, England, 1989, pp 3–22

    Google Scholar 

  23. Chiu KY, Loke SL, Wong KK: Improved silver technique for showing nucleolar organiser regions in paraffin wax sections. J Clin Pathol 42: 992–994, 1989

    PubMed  Google Scholar 

  24. Szepeshazi K, Korkut E, Schally AV: Decrease in AgNOR number in Dunning R 3327 prostate cancer after treatment with LH-RH agonist and antagonist. Am J Pathol 138: 1273–1277, 1991

    PubMed  Google Scholar 

  25. Srkalovic G, Szende B, Redding TW, Groot K, Schally AV: Receptors for D-Trp-6-luteinizing hormone-releasing hormone, somatostatin and insulin-like growth factor I in MXT mouse mammary carcinoma. Proc Soc Exp Biol Med 192: 209–218, 1989

    PubMed  Google Scholar 

  26. Munson PJ, Rodbard S: LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220–239, 1980

    Article  PubMed  Google Scholar 

  27. Watson C, Medina D, Clark JH: Estrogen receptor characterization in transplantable mouse mammary tumor. Cancer Res 37: 3344–3348, 1977

    PubMed  Google Scholar 

  28. Danguy A, Kiss R, Leclercq G, Heuson C, Pasteels JL: Morphology of MXT mouse mammary tumors. Correlation with growth characteristics and hormone sensitivity. Eur J Cancer Clin Oncol 22: 69–75, 1986

    Article  PubMed  Google Scholar 

  29. Kiss R, Paridaens R, Leclercq G, Danguy A: Sensitivity of the hormone dependent MXT-mouse mammary carcinoma to estradiol during tumoral growth. An autoradiographic study. Eur J Cancer Clin Oncol 22: 849–856, 1986

    Article  PubMed  Google Scholar 

  30. Matsuzawa A, Kaneko T, Ikeda Y: Accelerated progression to autonomy of a pregnancy-dependent mouse mammary tumor (TPDMT-4) by hormones. Cancer Res 43: 2283–2289, 1983

    PubMed  Google Scholar 

  31. Kiss R, de Launoit Y, Danguy A, Paridaens R, Pasteels J-L: Influence of pituitary grafts or prolactin administrations on the hormone sensitivity of ovarian hormone-independent mouse mammary MXT tumors. Cancer Res 49: 2945–2951, 1989

    PubMed  Google Scholar 

  32. Noguchi S, Tahara H, Miyauchi K, Koyama H: Influence of 1,25-dihydroxyvitamin D3 on the development and steroid receptor content of DMBA-induced rat mammary tumors. Oncology 46: 273–276, 1989

    PubMed  Google Scholar 

  33. Kyprianou N, English HF, Davidson NE, Isaacs JT: Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51: 162–166, 1991

    PubMed  Google Scholar 

  34. Crocker J: Nucleolar organizer regions. In: Underwood JCE (ed) Current Topics in Pathology. Springer Verlag, Heidelberg, London, 1990, pp 91–149

    Google Scholar 

  35. Derenzini M, Trere D: Importance of interphase nucleolar organizer regions in tumor pathology. Virchows Arch B Cell Pathol 61: 1–8, 1991

    Google Scholar 

  36. Lippman ME, Dickson RB, Gelmann EP, Rosen N, Knabbe C, Bates S, Bronzert D, Huff K, Kasid A: Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. J Cell Biochem 35: 1–16, 1987

    Article  PubMed  Google Scholar 

  37. Sainsbury JRC, Farndon JR, Sherbet GV, Harris AL: Epidermal-growth-factor receptors and oestrogen receptors in human breast cancers, Lancet i: 364–366, 1985

    Article  Google Scholar 

  38. Barker S, Puddefoot JR, Gledhill J, Miller P, Vinson GP: Control of epidermal growth factor receptors in breast cancer cell lines. J Endocrinol 124 (Suppl): 153, 1990

    Google Scholar 

  39. Toi M, Nakamura T, Mukaida H, Wada T, Osaki A, Yamada H, Toge T, Niimoto M, Hattori T: Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer 65: 1980–1984, 1990

    PubMed  Google Scholar 

  40. Harris AL: Epidermal growth factor receptor in human breast cancer. Rec Results Cancer Res 113: 70–77, 1989

    Google Scholar 

  41. Pekonen F, Partanen S, Makinen T, Rutanen E-M: Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48: 1343–1347, 1988

    PubMed  Google Scholar 

  42. Foekens JA, Portengen H, Janssen M, Klijn JGM: Insulin-like growth factor-I receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer 63: 2139–2147, 1989

    PubMed  Google Scholar 

  43. McCarty KS: Proliferative stimuli in the normal breast: estrogens or progestins? Human Pathol 20: 1137–1138, 1989

    Google Scholar 

  44. Ewing TM, Murphy LJ, Ng M-L, Pang GYN, Lee ChSL, Watts CKW, Sutherland RL: Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int J Cancer 44: 744–752, 1989

    PubMed  Google Scholar 

  45. Kurachi H, Okamoto S, Oka T: Evidence for the involvement of the submandibular gland epidermal growth factor in mouse mammary tumorigenesis. Proc Natl Acad Sci USA 82: 5940–5943, 1985

    PubMed  Google Scholar 

  46. Ennis BW, Valverius EM, Bates SE, Lippman ME, Bellot F, Kris P, Schlessinger J, Masui H, Goldenberg A, Mendelsohn J, Dickson RB: Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol 3: 1830–1838, 1989

    PubMed  Google Scholar 

  47. Robinson SP, Jordan VC: Antiestrogenic action of toremifene on hormone-dependent,-independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49: 1758–1762, 1989

    PubMed  Google Scholar 

  48. Rutqvist LE, Cedermark B, Fornander T, Glas U, Johansson H, Nordenskjold B, Rotstein S, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar M-L: The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 7: 1474–1484, 1989

    PubMed  Google Scholar 

  49. Pasqualini JR, Gelly C: Biological response of the anti-estrogen ICI 164,384 in human hormone-dependent and hormone-independent mammary cancer cell lines. Cancer Lett 50: 133–139, 1990

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, 70146, New Orleans, LA, USA

    Karoly Szepeshazi, Slobodan Milovanovic, Karoly Lapis, Kate Groot & Andrew V. Schally

  2. Department of Medicine, Tulane University Medical School, 70146, New Orleans, LA, USA

    Karoly Szepeshazi, Slobodan Milovanovic, Karoly Lapis, Kate Groot & Andrew V. Schally

  3. 1st Institute of Pathology and Experimental Cancer Research, Semmelweis University Medical School, Budapest, Hungary

    Karoly Lapis

Authors
  1. Karoly Szepeshazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Slobodan Milovanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karoly Lapis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kate Groot
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrew V. Schally
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Szepeshazi, K., Milovanovic, S., Lapis, K. et al. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Tr 21, 181–192 (1992). https://doi.org/10.1007/BF01975001

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01975001

Key words

Search

Navigation